|Bid||73.76 x 100|
|Ask||74.08 x 100|
|Day's Range||73.28 - 74.41|
|52 Week Range||63.76 - 88.85|
|PE Ratio (TTM)||7.80|
|Dividend & Yield||2.08 (2.86%)|
|1y Target Est||N/A|
IBD's 439-company Biotech industry group is now ranked fourth out of 197. How far can the rally go?
Is Gilead Sciences (GILD) poised for a beat next week? Guggenheim analyst Tony Butler sees Gilead earning $2.15 a share, a penny above the consensus forecast compiled by sell-side analyst, with operating revenue of $6.54 billion beating the $6.31 billion expected by the Street. Butler’s estimates for the full 2017 calendar year are also above consensus, with per-share earnings of $8.28 on operating revenue of $25.4 billion.
Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Jul 27, before the opening bell. Last quarter, the company beat earnings estimates by 16.7%.